EcoDrugPlus

Purinergic Receptor P2y2

Ensembl ID : ENSNFUG00015002200
Gene Symbol: P2RY2
1 Cross references
197 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSNFUG00015002181
Gene Symbol: P2RY4
1 Cross references
165 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSNFUG00015002275
Gene Symbol: P2RY6
3 Cross references
182 Possible Orthologues:

Receptor (Tnfrsf)-Interacting Serine-Threonine Kinase 1, Like

Ensembl ID : ENSNFUG00015023069
Gene Symbol: RIPK1L
1 Cross references
197 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSNFUG00015003186
Gene Symbol: RAMP1
3 Cross references
184 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSNFUG00015010334
Gene Symbol: RAMP1
3 Cross references
191 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-2-Like

Ensembl ID : ENSNFUG00015022315
Gene Symbol: LOC107387934
3 Cross references
200 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-3-Like

Ensembl ID : ENSNFUG00015008835
Gene Symbol: LOC107390894
3 Cross references
206 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-4-Like

Ensembl ID : ENSNFUG00015018445
Gene Symbol: LOC107372717
2 Cross references
47 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSNFUG00015020831
Gene Symbol: RPTOR
3 Cross references
213 Possible Orthologues:

Renin

Ensembl ID : ENSNFUG00015024819
Gene Symbol: REN
3 Cross references
219 Possible Orthologues:

Retinoic Acid Receptor Rxr-Beta-A-Like

Ensembl ID : ENSNFUG00015002175
Gene Symbol: LOC107378676
3 Cross references
211 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).